Supplementary Data from PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses Against Tumor

Liangrong Shi,Lujun Chen,Changping Wu,Yibei Zhu,Bin Xu,Xiao Zheng,Mingfen Sun,Wen,Xichao Dai,Min Yang,Quansheng Lv,Binfeng Lu,Jingting Jiang

DOI: https://doi.org/10.1158/1078-0432.22457843

2023-01-01

Abstract:Supplemental figure 1. Patient cohort and study design. Supplemental Figure 2. Immunochemical staining of PD-L1 antibody (1:500, clone: SP142) on the paraffin-embedded human melanoma and placenta tissues. Supplemental Figure 3. RFA of colorectal liver metastases increased PD-L1 expression on infiltrating immune cells. Supplemental Figure 4. Correlation between PD-L1 expression on tumor cells and the intensity of CD8+, CD4+ T cell infiltration in endoscopic biopsy (A, B) and resected tumor specimen (C, D) (all of 78 patients were included). Supplemental Figure 5. RFA increased CD45+ immune cells and T cells infiltrating into contralateral tumor. Supplemental Figure 6. RFA increased T cells infiltration and PD-1/PD-L1 expression in a disdant tumor in B16 tumor-bearing mice. Supplemental Figure 7. RFA did not upregulate PD-1/PD-L1 expression in splenic lymphocytes. Supplemental Figure 8. RFA increased Tim-3, CD160, CD244 and eomes expression in a disdant tumor in CT26 tumor-bearing mice. Supplemental Figure 9. RFA and the anti-PD-1 therapy increased CD8+TIL cell infiltration in distant tumor. Supplemental Figure 10. RFA and the anti-PD-1 therapy upregulated Tim-3 expression on T cells in a distant tumor. Supplemental Table 1 Primer sequences used for the detection of gene expression by RT-QPCR Supplemental Table 2 Patient characteristic Supplemental table 3. Multivariate analysis of factors related to increased PD-L1 expression in resected tumor specimen.